Elahere approved in EU as treatment for advanced ovarian cancer
AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
AbbVie (NYSE:ABBV) announced that it began construction for a $70 million expansion of its bioresearch center (ABC) in Worcester, Massachusetts. The ABC in Worcester serves as a center of excellence for biologics R&D and manufacturing. AbbVie said its latest expansion comes as part of a plan to invest more than $10 billion in the U.S.… The post AbbVie invests $70M in U.S. biologics manufacturing, R&D expansion appeared first on Pharmaceutical Processing World.| Pharmaceutical Processing World
The pharmaceutical blockbuster model is wobbling. And no single franchise is safe. While king Keytruda, Merck’s stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S. patent expiry in 2028 the single biggest loss of exclusivity event on the horizon. In the U.S., Medicare… The post Top 25 drugs by sales: 2025 H1 appeared first on Drug Discovery and Development.| Drug Discovery and Development
AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
